Gland Pharma Past Earnings Performance
Past criteria checks 2/6
Gland Pharma has been growing earnings at an average annual rate of 1.5%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 12.7% per year. Gland Pharma's return on equity is 7.9%, and it has net margins of 13.4%.
Key information
1.5%
Earnings growth rate
0.04%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 12.7% |
| Return on equity | 7.9% |
| Net Margin | 13.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Gland Pharma (NSE:GLAND) A Risky Investment?
Mar 19
Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion
Feb 16Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher
May 20Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 07Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers
Jul 22Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?
Jul 14Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?
Feb 08A Look At The Intrinsic Value Of Gland Pharma Limited (NSE:GLAND)
Jul 05Gland Pharma (NSE:GLAND) Strong Profits May Be Masking Some Underlying Issues
May 24Gland Pharma Limited (NSE:GLAND) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 19Gland Pharma Limited's (NSE:GLAND) 27% Price Boost Is Out Of Tune With Earnings
Mar 04Gland Pharma Limited's (NSE:GLAND) Stock Is Going Strong: Is the Market Following Fundamentals?
Feb 20Revenue & Expenses BreakdownBeta
How Gland Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 49,123 | 6,587 | 10,117 | 0 |
| 30 Sep 23 | 43,054 | 6,988 | 7,675 | 0 |
| 30 Jun 23 | 39,764 | 7,460 | 5,603 | 0 |
| 31 Mar 23 | 36,246 | 7,810 | 4,069 | 0 |
| 31 Dec 22 | 39,426 | 9,883 | 3,961 | 0 |
| 30 Sep 22 | 40,676 | 10,293 | 3,764 | 0 |
| 30 Jun 22 | 41,037 | 10,902 | 3,560 | 0 |
| 31 Mar 22 | 44,007 | 12,117 | 3,400 | 0 |
| 31 Dec 21 | 41,854 | 11,862 | 3,237 | 0 |
| 30 Sep 21 | 39,815 | 11,172 | 3,245 | 0 |
| 30 Jun 21 | 37,326 | 10,340 | 3,196 | 0 |
| 31 Mar 21 | 34,629 | 9,970 | 3,125 | 0 |
| 31 Dec 20 | 32,104 | 9,313 | 3,026 | 0 |
| 30 Jun 20 | 28,430 | 9,027 | 2,838 | 0 |
| 31 Mar 20 | 26,332 | 7,729 | 2,800 | 0 |
| 31 Mar 19 | 20,442 | 4,519 | 2,332 | 0 |
| 31 Mar 18 | 16,199 | 3,211 | 1,827 | 0 |
| 31 Mar 17 | 14,792 | 4,137 | 1,608 | 0 |
Quality Earnings: GLAND has high quality earnings.
Growing Profit Margin: GLAND's current net profit margins (13.4%) are lower than last year (25.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLAND's earnings have grown by 1.5% per year over the past 5 years.
Accelerating Growth: GLAND's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GLAND had negative earnings growth (-33.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.8%).
Return on Equity
High ROE: GLAND's Return on Equity (7.9%) is considered low.